Amphastar Pharmaceuticals, Inc.
Moat Score — Amphastar Pharmaceuticals, Inc.
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Amphastar holds ANDA approvals and manufacturing know-how for technically complex injectable and inhalation products that took years to develop and validate, along with FDA approval for its proprietary Primatene Mist product, both of which are difficult for new entrants to quickly replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Vertical integration into in-house API manufacturing for products like enoxaparin gives Amphastar real cost and supply-chain control advantages versus less-integrated generic competitors reliant on third-party API sourcing. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | By deliberately targeting technically complex generics with fewer qualified competitors, Amphastar maintains meaningfully better pricing power than typical commodity oral generic manufacturers, though pricing still faces gradual erosion as additional competitors gain approval. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical manufacturing and distribution exhibit no network effect; the value of Amphastar's products to one hospital or distributor does not increase because other customers also purchase them. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Hospitals and distributors generally qualify multiple suppliers for critical injectables to ensure supply continuity, giving Amphastar some but not extensive switching-cost protection, reinforced somewhat by supply reliability concerns following past industry-wide drug shortages. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The regulatory and manufacturing complexity required to produce technically difficult injectables like enoxaparin or emergency-use epinephrine naturally limits the number of qualified competitors, giving Amphastar real efficient-scale protection within its chosen niches. |